Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

As for the ability of tissue SERPINB10 to be a predictive indicator of postop CRSwNP recurrence, although a link was seen between CRSwNP recurrence and tissue eosinophil percentage (odds ratio [OR ...

Most people with a condition known as chronic rhinosinusitis with nasal polyps (CRSwNP) are able to control their symptoms by using medicines that are sprayed into the nose or taken by mouth. But ...

CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages.

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials (ClinicalTrials.gov Identifier: NCT02912468 and NCT02898454, respectively), which compared ...

Comprehensive research reveals significant insights into the burgeoning market for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), providing in-depth analysis that predicts a striking growth ...

Among patients in the dupilumab/dupilumab group, 71.4% of those with CRSwNP and 83.3% of those without CRSwNP no longer needed OCS, with corresponding rates of 38.5% and 46.7% in the placebo ...

Patients also used mometasone furoate nasal spray. “Dupilumab outperformed omalizumab on all endpoints in both CRSwNP and asthma, while showing generally similar safety profiles,” De Corso said.

For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...

De Corso E, Baroni S, Onori ME, et al. Calprotectin in nasal secretion: a new biomarker of non-type 2 inflammation in CRSwNP. Acta Otorhinolaryngal Ital. Published online June 30, 2022. doi:10. ...